Document Detail


The Role of Metastasectomy in Renal Cell Carcinoma in the Era of Targeted Therapy.
MedLine Citation:
PMID:  23212738     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Despite contemporary innovations in systemic therapy and surgical treatment, renal cell carcinoma (RCC) remains the most lethal urologic malignancy. Still, around 20 % of patients with RCC present with metastases at diagnosis, and 40-50 % of those with localized advanced disease will ultimately progress to metastatic disease. Although the new, targeted therapy paradigms have changed the treatment of patients with advanced RCC and offer prolonged survival, cure is extremely uncommon in the absence of surgical resections. In this paper, the current role of metastasectomy is reviewed. Searches were carried out in the PubMed database and the Cochrane Library of Controlled Clinical Trials. While there is no randomized study available, recent large observational studies have better defined the prognosis of patients with metastatic RCC with or without metastasectomy. In multivariate analysis, independent predictive factors included male gender, disease-free interval > 1 year, single metastatic site and complete metastasectomy. Other reports from selected patient materials show 29-31 % 5-year overall survival rates. In patients with recurrent disease after resection of a lung metastasis, 60 % were able to undergo a subsequent resection, compared with 25 % with recurrent bone metastasis. Also, metastasectomy after initial systemic therapy gave partial or complete response in a majority of patients. In these patients, the median survival was 4.7 years and 21 % remained free of disease at last follow-up. Patients with metastatic renal cell carcinoma should be considered for multimodal therapy, including surgery of metastatic lesions. A proportion of patients will achieve long-term survival with aggressive surgical resection.
Authors:
Börje Ljungberg
Related Documents :
12507088 - Gamma knife radiosurgery for brain metastases: a primary therapeutic option.
15791468 - Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or s...
24480828 - Challenges and advances in the treatment of aki.
2707088 - Surgical treatment of primary lung cancer and solitary intracranial metastasis.
19837688 - Prognostic stratification in patients who received hormonal therapy for prostate-specif...
10949388 - Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etop...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-5
Journal Detail:
Title:  Current urology reports     Volume:  -     ISSN:  1534-6285     ISO Abbreviation:  Curr Urol Rep     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100900943     Medline TA:  Curr Urol Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, 901 85, Umeå, Sweden, Borje.Ljungberg@urologi.umu.se.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  It takes two to tango - signalling by dimeric Raf kinases.
Next Document:  West Nile virus associations in wild mammals: a synthesis.